Juan Pablo Alderuccio

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio et al. · The Lancet Oncology · 2021 · 417 citations

Medicine, Oncology, Pharmacotherapy +10

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey V. Danilov, Deepa Jagadeesh et al. · Blood · 2021 · 124 citations · Full text

Medicine, Oncology, Pathology +12

Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution

Juan Pablo Alderuccio, Wei Zhao, Amrita Desai et al. · Journal of Clinical Oncology · 2018 · 79 citations

Medicine, Oncology, Pathology +10

Bilateral radiation therapy followed by methotrexate‐based chemotherapy for primary vitreoretinal lymphoma

Macarena I. de la Fuente, Juan Pablo Alderuccio, Isildinha M. Reis et al. · American Journal of Hematology · 2019 · 60 citations · Full text

Medicine, Oncology, Ophthalmology +13

HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis

Juan Pablo Alderuccio, Adam J. Olszewski, Andrew M. Evens et al. · Blood Advances · 2021 · 53 citations · Full text

Medicine, Oncology, Chemotherapy +7